AT525083T - A pharmaceutical composition comprising an insulinotropic GLP-1 (7-37) analog Asp (B28) - insulin and a surface active compound - Google Patents

A pharmaceutical composition comprising an insulinotropic GLP-1 (7-37) analog Asp (B28) - insulin and a surface active compound

Info

Publication number
AT525083T
AT525083T AT04797450T AT04797450T AT525083T AT 525083 T AT525083 T AT 525083T AT 04797450 T AT04797450 T AT 04797450T AT 04797450 T AT04797450 T AT 04797450T AT 525083 T AT525083 T AT 525083T
Authority
AT
Austria
Prior art keywords
b28
insulin
pharmaceutical composition
active compound
surface active
Prior art date
Application number
AT04797450T
Other languages
German (de)
Inventor
Liselotte Bjerre Knudsen
Kristian Tage Hansen
Dorthe Kot Engelund
Svend Ludvigsen
Lars Hansen
Claude Bonde
Ejvind Jensen
Tine Elisabeth Gottschalk Boving
Morten Schlein
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DKPA200301689 priority Critical
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to PCT/DK2004/000788 priority patent/WO2005046716A1/en
Publication of AT525083T publication Critical patent/AT525083T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
AT04797450T 2003-11-13 2004-11-12 A pharmaceutical composition comprising an insulinotropic GLP-1 (7-37) analog Asp (B28) - insulin and a surface active compound AT525083T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DKPA200301689 2003-11-13
PCT/DK2004/000788 WO2005046716A1 (en) 2003-11-13 2004-11-12 Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia

Publications (1)

Publication Number Publication Date
AT525083T true AT525083T (en) 2011-10-15

Family

ID=34585770

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04797450T AT525083T (en) 2003-11-13 2004-11-12 A pharmaceutical composition comprising an insulinotropic GLP-1 (7-37) analog Asp (B28) - insulin and a surface active compound

Country Status (5)

Country Link
EP (1) EP1684793B1 (en)
JP (1) JP4800959B2 (en)
AT (1) AT525083T (en)
ES (1) ES2373660T3 (en)
WO (1) WO2005046716A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2298378T3 (en) 2001-06-28 2008-05-16 Novo Nordisk A/S Stable formulation of GLP-1 modified.
US7530968B2 (en) 2003-04-23 2009-05-12 Valeritas, Inc. Hydraulically actuated pump for long duration medicament administration
AT541582T (en) 2003-06-03 2012-02-15 Novo Nordisk As A stabilized pharmaceutical compositions of the GLP-1 peptide
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN1882356B (en) * 2003-11-20 2015-02-25 诺沃挪第克公司 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
JP4965446B2 (en) 2004-08-31 2012-07-04 ノヴォ ノルディスク アー/エス Peptides, tris (hydroxymethyl) for the stabilization of polypeptides and proteins used in aminomethane
EP1814581B1 (en) * 2004-11-12 2016-03-16 Novo Nordisk A/S Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
CN102772787A (en) * 2004-11-12 2012-11-14 诺和诺德公司 Stable formulations of insulinoptropic peptides
SG173319A1 (en) 2006-03-30 2011-08-29 Valeritas Inc Multi-cartridge fluid delivery device
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
ES2612736T3 (en) 2007-11-16 2017-05-18 Novo Nordisk A/S Stable pharmaceutical compositions comprising liraglutide and degludec
CA2708762A1 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
KR20100111682A (en) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 Novel insulin derivatives having an extremely delayed time-action profile
CN105396126A (en) * 2008-10-17 2016-03-16 赛诺菲-安万特德国有限公司 Combination Of An Insulin And A GLP-1 Agonist
TWI507190B (en) 2009-11-13 2015-11-11 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
RU2573995C2 (en) 2009-11-13 2016-01-27 Санофи-Авентис Дойчланд Гмбх Pharmaceutical composition containing glp-1 agonist and methionine
AU2011206629B2 (en) * 2010-01-12 2014-07-17 Novo Nordisk A/S Pharmaceutical compositions for oral administration of insulin peptides
RS55378B1 (en) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CA2846413A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AR092862A1 (en) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Liquid formulation of long-acting insulin and an insulinotropic peptide and preparation method
RS57531B1 (en) 2012-12-21 2018-10-31 Sanofi Sa Exendin-4 derivatives as dual glp1/gip- or trigonal glp1/gip/glucagon agonists
TWI641381B (en) 2013-02-04 2018-11-21 法商賽諾菲公司 Insulin analogues and / or stabilization of the insulin derivative pharmaceutical formulations
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (en) 2013-12-13 2016-03-16 Sanofi Sa Non-acylated EXENDIN-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CA2932875A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
TW201625669A (en) 2014-04-07 2016-07-16 Sanofi Sa Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 Sanofi Sa Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 Sanofi Sa Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016092026A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TW201705975A (en) 2015-03-18 2017-02-16 Sanofi Aventis Deutschland Treatment of type 2 diabetes mellitus patients
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa Exendin-4 derivatives as dual specific peptide agonists receptor glp-1 / glucagon

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE122009000079I2 (en) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle GLP-1 derivatives
EP0929576A1 (en) * 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivatives
DK1629849T4 (en) * 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exediner and agonists thereof,
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
EP1250126A2 (en) * 2000-01-11 2002-10-23 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin

Also Published As

Publication number Publication date
EP1684793A1 (en) 2006-08-02
JP4800959B2 (en) 2011-10-26
WO2005046716A1 (en) 2005-05-26
EP1684793B1 (en) 2011-09-21
ES2373660T3 (en) 2012-02-07
JP2007510675A (en) 2007-04-26

Similar Documents

Publication Publication Date Title
AU765588C (en) Cytotoxic agents comprising taxanes and their therapeutic use
TWI293626B (en) Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
RU2004110726A (en) Use of oxyntomodulin, a method and pharmaceutical composition for the prevention or treatment of excess weight, a method of reducing body weight
RU2002125821A (en) The solid simethicone dosage forms for oral use
NO20034268D0 (en) Intravaginal drug delivery devices for administering an antimicrobial agent
RU2000123156A (en) Rapidly cleaved pharmaceutical dosage form
RU2003136754A (en) Improvements in the delivery of programs
ZA200204960B (en) Hydrogel-driven drug dosage form.
CL2008000762A1 (en) Pyrimidine derivatives compounds; pharmaceutical composition comprising said compounds; and their use for the treatment of psoriasis, diabetes, rheumatoid arthritis, among other diseases (divisional 1147-1102).
RU2007119990A (en) Drug fusions and conjugates
RU2007118700A (en) The insecticide, acaricide and nematicide containing, as an active ingredient, the 3-triazolilfenilsulfida
BR0107445B1 (en) pharmaceutical formulation, and use of fulvestrant in the preparation of a pharmaceutical formulation.
AT416771T (en) N-ä4- (4-amino-2-ethyl-1H-imidazoä4,5 cüchinolin-1-yl) butylümethanesulfonamide, pharmaceutical composition containing and the use thereof
DE50012448D1 (en) Sustained release, oral pharmaceutical darreichnungsformen with tramadol
RU2001129372A (en) The water-soluble composition bioactive lipophilic compounds
DE60031999D1 (en) Stabilized liquid pharmaceutical composition comprising polypeptide
DE122011100047I1 (en) A solid pharmaceutical dosage forms with einemS1P receptor agonist and a sugar alcohol.
HU0400932A3 (en) Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the same
EE200300312A (en) Quinuclidine derivative, obtaining and preparing a drug intended for the respiratory, urinary or gastrointestinal diseases, and a pharmaceutical composition comprising
AT507828T (en) New pyrroles with hypolipidemic and hypocholesterischer activity, manufacturing process, these pharmaceutical compositions containing them and their medical use
NZ527392A (en) Methods of treating diabetes mellitus
EE200300171A (en) The crystalline monohydrate, methods for its preparation and its use in the manufacture of a pharmaceutical composition
NO320909B1 (en) Pyrimidine compounds and their use and the preparation thereof and pharmaceutical compositions.
NO322701B1 (en) Benzylidene thiazolidinediones, use and preparation thereof, and pharmaceutical compositions.
RU2006120441A (en) The combination of the active substances with insecticidal properties

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties